In addition, if this combination therapy is a worthwhile option, more thorough clinicopathological characteristics and biomarkers of HER2+ BC sensitivity to CDK4/6i merit further investigation in pre-clinical research. This evidence concerns the gene ERBB2 and breast cancer.